Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

• Sponsor: Stanford University (Other)
• Overall Status: Terminated
• CT.gov ID: NCT01326364
• Collaborator: (none)
• Enrollment: 6
• Location: 1
• Duration (Months): 27
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.

Condition or Disease	Intervention/Treatment	Phase
Pancreatic Cancer	Procedure: Stereotactic body radiotherapy; Drug: Iodixanol; Drug: Iohexol

Study Design

• Study Type: Observational
• Actual Enrollment: 6 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
• Study Start Date: Mar 1, 2010
• Actual Primary Completion Date: Jun 1, 2012
• Actual Study Completion Date: Jun 1, 2012

Outcome Measures

Primary Outcome Measures

1. Histological markers of tumor angiogenesis (microvessel density, EGF/VEGF expression level) [1 day]

2. Tumor response to treatment in SBRT patients, based on WHO criteria (No Change/Progressive Disease vs. Partial/Complete Response) [1 year]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. suspected and/or biopsy-proven pancreatic adenocarcinoma, and

2. referral to Radiology for pre-treatment baseline pancreatic protocol CT.

Exclusion criteria:

1. are absolute contraindications to intravenous iodinated contrast or CT scan.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Stanford University School of Medicine	Stanford	California	United States	94305

Sponsors and Collaborators

• Stanford University

Investigators

• Principal Investigator: Aya Kamaya, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Stanford University
• ClinicalTrials.gov Identifier: NCT01326364
• Other Study ID Numbers: PANC0009; SU-03182010-5282
• First Posted: Mar 30, 2011
• Last Update Posted: Jul 1, 2016
• Last Verified: Jun 1, 2016

• Additional relevant MeSH terms: Pancreatic Neoplasms

Study Results

No Results Posted as of Jul 1, 2016